May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
FGF2, Müller Glia and Neuroprotection in the Chicken Retina
Author Affiliations & Notes
  • E. R. Ritchey
    Ohio State University, Columbus, Ohio
    College of Optometry,
  • M. A. Scott
    Ohio State University, Columbus, Ohio
    Department of Neuroscience,
  • A. J. Fischer
    Ohio State University, Columbus, Ohio
    Department of Neuroscience,
  • Footnotes
    Commercial Relationships  E.R. Ritchey, None; M.A. Scott, None; A.J. Fischer, None.
  • Footnotes
    Support  NIH Grant EY015447 (ERR), NIH Grant EY016043 (AJF)
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2075. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. R. Ritchey, M. A. Scott, A. J. Fischer; FGF2, Müller Glia and Neuroprotection in the Chicken Retina. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2075. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Current research in neuroprotection and the retina has focused on improving the resistance of neurons to damage. To date, the role of improving the neuroprotective properties of Müller glia is poorly understood. We examine the role of FGF2 on Müller glia and neuroprotection in the chicken retina.

Methods: : White leghorn chickens received intravitreal injections of either 0.2µg of FGF2, 1µg insulin, FGF2+insulin or the MAP Kinase inhibitor UO126 on postnatal days 5 and 6. On postnatal day 7, all eyes received 1µg NMDA treatment. At postnatal day 8, all eyes received BrdU and were sacrificed 4 hours after injection. Retinas were fixed, sectioned and labeled for TUNEL, BrdU, PCNA, cFos, Egr1 and pCREB.

Results: : In response to FGF2 treatment, levels of cFos and pCREB increase in Müller glia. Similarly, treatment with insulin increases levels of cFos and pCREB as well Egr1 in the Müller glia. FGF2 prior to NMDA treatment caused a significant reduction in the number of TUNEL positive cells in the Inner Nuclear Layer (INL). Insulin prior to NMDA treatment caused a significant increase in the number of TUNEL positive cells in the INL. Treatment with FGF2 + insulin showed no decrease in the number of TUNEL positive cells compared to insulin treatment alone. Treatment with UO126 prior to NMDA produced a significant reduction in TUNEL positive cells in the INL. BrdU and PCNA labeling is increased in the Müller glia in peripheral retina with FGF2 treatment compared to control retinas, where it is not increased in central retina.

Conclusions: : The upregulation of cFos and pCREB selectively in Müller glia indicates that the neuroprotective effects of FGF2 may be mediated through the activity of Müller glia. Upregulation of Egr1 in insulin treated eyes, but not in FGF2 treated eyes, suggests that Egr1 may be associated with a loss of neuroprotective capacity. The reduction in TUNEL positive cells resulting from UO126 treatment suggests that FGF2-independent MAP Kinase signaling may normally protect inner retinal neurons from excitotoxicity.

Keywords: neuroprotection • Muller cells • retina 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×